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Despite advances in treatment for metastatic prostate cancer, patients eventually progress
to castrate-resistant disease and ultimately succumb to their cancer. Androgen depriva-
tion therapy (ADT) is the standard treatment for metastatic prostate cancer and has been
shown to improve median time to progression and median survival time. Research sug-
gests that castrate-resistant clones may be present early in the disease process prior to
the initiation of ADT.These clones are not susceptible to ADT and may even flourish when
androgen-responsive clones are depleted. Stereotactic body radiation therapy (SBRT) is a
safe and efficacious method of treating clinically localized prostate cancer and metastases.
In patients with a limited number of metastatic sites, SBRT may have a role in eliminating
castrate-resistant clones and possibly delaying progression to castrate-resistant disease.
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STEREOTACTIC BODY RADIATION THERAPY
Radiation oncologists strive to maximize tumor control while
minimizing normal tissue toxicity. Over the past several years,
advances in image-guided radiation treatment (IGRT) have
allowed the treatment of tumors with increased efficacy and
reduced toxicity (1–4). For example, stereotactic body radia-
tion therapy (SBRT) may improve tumor control and reduce
treatment-related toxicity through improved targeting and man-
agement of tumor motion (5). Accurate tumor targeting means
that radiation may be delivered with relatively narrow margins
to account for uncertainty in target position. This allows for
high-dose, extremely hypofractionated treatment courses (1–5
fractions) that may be more radiobiologically effective and are
certainly more convenient for patients (6, 7). For example, the
CyberKnife Radiosurgical System (Accuray) is capable of localiz-
ing the prostate and adjusting the radiation beam accordingly in
real time throughout a treatment fraction (8). This feature allows
for a reduction in the planning target volume (PTV) and therefore
better limits the dose to adjacent rectum and bladder (Figure 1).
Multi-institutional experience demonstrates that this technology
Abbreviations: ADT, androgen deprivation therapy; CRPC, castrate-resistant
prostate cancer; DVH, dose-volume histogram; GTV, gross target volume; IGRT,
image-guided radiation treatment; LHRH, luteinizing hormone-releasing hormone;
PAP, prostatic acid phosphatase; PSA. prostate-specific antigen; PTV, planning target
volume; SBRT, stereotactic body radiation therapy; TURP, transurethral resection
of the prostate.
allows investigators to administer higher doses to the prostate
with biochemical disease-free survival and toxicity rates similar
to conventional treatments (9–14). It is hoped that SBRT will
also positively impact patient outcomes in patients with limited
metastatic disease.
OLIGOMETASTASES
Patients with controlled primaries and “oligometastatic” disease
may experience long-term stability in the number of metasta-
tic sites (15). Oligometastatic prostate cancer has been defined
as five or fewer sites due to the more favorable outcomes seen
in these patients (Figure 2) (16). Hellman and Weichselbaum first
proposed the existence of oligometastatic disease as a clinically sig-
nificant state separate from polymetastatic disease and suggested a
more causal relationship between the size or grade of a tumor and
its propensity for metastatic spread (17). Corbin et al. expanded on
this concept suggesting the development of a specific oligometasta-
tic phenotype over the natural course of a cancer’s evolution that is
less aggressive than other metastatic phenotypes (18). This theory
has been corroborated by microRNA analysis of clinically limited
metastatic disease that accurately characterizes which patients will
remain oligometastatic and which patients will proceed to poly-
metastatic disease (19). For patients with limited metastatic sites,
SBRT to the oligometastases may offer long-term disease control
and impact survival (20). Data are emerging that patients with lim-
ited asymptomatic metastases may experience improved disease-
free survival and quality of life after SBRT (21). We hypothesize
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FIGURE 1 | Prostate SBRT: treatment planning axial computed
tomography images demonstrating the prostate (red line), prostatic
urethra (yellow), and rectum (green line). Isodose lines shown as
follows: 115% of the prescription dose, maroon line; 100% of the
prescription dose, light blue line: 75% of the prescription dose, orange line;
and 35% of the prescription dose, green line.
that in oligometastatic prostate cancer patients, androgen depri-
vation therapy (ADT) would eliminate micrometastatic disease
while SBRT would eradicate large tumor deposits that may be
more likely to develop castrate-resistant clones.
ANDROGEN DEPRIVATION THERAPY FOR METASTATIC
PROSTATE CANCER
The current treatment for newly diagnosed metastatic prostate
cancer is hormone ablation via luteinizing hormone-releasing
hormone (LHRH) analog until disease progression (22). The
response rate for primary hormonal therapy for men with metasta-
tic prostate cancer exceeds 80% and the median duration of
response is approximately 18–24 months (22). Patients with high
volume metastatic disease have a poorer prognosis with a median
time to prostate-specific antigen (PSA) progression of about only
10 months and median time to clinical progression (e.g., worsen-
ing bone metastases) of about 14 months (23). In contrast, patients
with low volume metastatic disease have a 22-month median time
to PSA progression with androgen ablation alone and median time
to clinical progression of more than 3 years (23). The median over-
all survival for men commencing androgen ablation with clinically
evident metastatic disease is about 30 months (22). Survival varies
depending on the extent of disease and location of the bone metas-
tases (16, 23–27). All patients will ultimately progress despite the
initial success of this approach. Castrate-resistant prostate cancer
(CRPC) remains an incurable disease resulting in considerable
morbidity. Alternative hormonal agents or chemotherapy may
FIGURE 2 | Sixty-year-old gentleman with oligometastatic prostate
cancer. He presented with back pain and his PSA was 35 ng/ml. DRE was
abnormal and imaging revealed: (A) Coronal T2-weighted multiplanar
reconstruction MRI image demonstrating extracapsular extension into the
seminal vesicles. (B) Bone scan demonstrating a solitary L5 vertebral body
metastasis.
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be employed at the time of castrate resistance and provide small
overall survival benefits (28).
CHEMOTHERAPEUTIC AGENTS FOR CASTRATE-RESISTANT
PROSTATE CANCER
Early investigation of chemotherapeutic agents for metastatic
CRPC showed that mitoxantrone combined with prednisone
improved pain and quality of life when compared to pred-
nisone alone (29, 30). Unfortunately, mitoxantrone did not pro-
long survival in randomized trials (31, 32). Docetaxel was the
first chemotherapeutic agent able to demonstrate increased sur-
vival in metastatic CRPC in addition to decreased pain and
improved quality of life (33). Median survival increased by
2.9 months in the cohort who received docetaxel compared to
mitoxantrone.
The breakthrough with docetaxel has led to subsequent
advances in systemic therapy for metastatic prostate cancer. Mul-
tiple hormonal and non-hormonal agents have emerged in recent
phase III clinical trials that demonstrate increased overall survival
time (outlined in Tables 1 and 2) (34–39). Hormonal agents target
adrenal testosterone production that is shielded from conven-
tional ADT. Abiraterone inhibits androgen production by block-
ing enzymes crucial to testosterone synthesis (34). Enzalutamide
does not lower intratumoral testosterone but is a potent andro-
gen receptor antagonist that acts by blocking androgen activity
within cancer cells (36). Novel non-hormonal agents have also
been efficacious in the setting of CRPC. Sipuleucel-T is a thera-
peutic cancer vaccine that acts as an immunostimulant specifically
targeting the prostatic acid phosphatase (PAP) antigen found on
prostate cancer cells (37). Radium-223 is a radiopharmaceutical
agent that targets bony tissue and destroys metastatic prostate can-
cer cells through alpha particle emission (38). Additional phase III
trials with newer agents are underway. To date, no single agent
has demonstrated a PSA response rate greater than 54% or an
overall survival benefit greater than 5 months, and further inno-
vation through new agents or combination regimens is necessary
to optimize survival.
RATIONALE FOR TREATMENT OF THE PROSTATE IN THE
PRESENCE OF OLIGOMETASTATIC DISEASE
We believe an effective radiotherapeutic approach in the prostate
may improve long-term outcomes with limited toxicity in patients
with oligometastatic disease. The addition of prostate radiother-
apy to ADT has been shown to significantly improve progression-
free survival and overall survival with acceptable morbidity in
patients with locally advanced prostate cancer (40, 41). While a
slight increase in overall bother from urinary and bowel symp-
toms may occur from combined therapy, the difference is minimal
and does not meet the threshold for clinical significance (42). The
SPCG-7/SFUO-3 trial for patients with locally advanced prostate
cancer achieved a 12% reduction in 10-year prostate cancer spe-
cific mortality when radiotherapy was combined with endocrine
treatment (41). The trial observed a 10-year overall survival benefit
of 8.9% consistent with a 7-year overall survival benefit of 8% with
the addition of radiation therapy in the NCIC CTG PR.3/MRC UK
PR07 trial (40, 41).
The mechanism of such benefit is currently unclear. Castrate-
resistant clones may be present in the prostate prior to the
initiation of ADT and they could be enriched through clonal selec-
tion after testosterone decline (Figure 3) (43). Animal models
support the use of early local treatment to eliminate androgen-
independent clones (44, 45). Radiotherapy, which eradicates
androgen-sensitive and androgen insensitive clones with similar
efficacy, may be effective at eradicating androgen-independent
clones. This has the potential to delay the time to castrate resistance
and hence prolong disease control.
Studies in which routine post-radiotherapy prostate biopsies
have been performed following primary ADT reveal a high rate
of persistence of local disease (46). In the SPCG-7 trial, the post-
radiation therapy biopsy positivity rate was an unacceptable 66%
(46). Local control is important in this malignancy, as problems
resulting from uncontrolled local disease are significant including
urinary obstruction (47). Palliative transurethral resection of the
prostate (TURP) and/or radiation therapy may be less effective
than primary treatment when the disease burden is lower (48, 49).
Table 1 | Prostate-specific antigen response rate of new chemotherapeutic agents for metastatic CRPC.
Trial Treatment
group
Drug class Mechanism of action Control group Treatment
group response
rate (%)
Control
group response
rate (%)
P -value
TAX 327 Docetaxel+
prednisone
Taxoid Microtubule disassembly
inhibitor
Mitoxantrone+
prednisone
45 32 <0.001
TROPIC Cabazitaxel+
prednisone
Taxoid Microtubule disassembly
inhibitor
Mitoxantrone+
prednisone
39.2 17.8 =0.0002
COU-AA301 Abiraterone+
prednisone
Hormonal agent Cytochrome P4S0 17A1
inhibitor
Placebo+
prednisone
29 6 <0.001
AFFIRM En2alutamide Hormonal agent Androgen receptor antagonist Placebo 54 2 <0.001
IMPACT Sipuleucel-T Cancer vaccine PA2024 activated peripheral-
blood mononuclear cells
Placebo 2.6 1.3 Not
significant
ALSYMPCA Radium-223 Radio pharmaceutical Bone-targeted alpha radiation Placebo 16 6 <0.001
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Table 2 | Overall survival benefit of new chemotherapeutic agents for metastatic CRPC.
Trial Patients Treatment group Control group Median improvement
in overall survival
(months)
P -value
TAX 327 1006 Docetaxel+prednisone Mitoxantrone+prednisone 2.9 =0.004
TROPIC 755 Cabazitaxel+prednisone Mitoxantrone+prednisone 2.4 <0.0001
COU-AA-301 119S Abiraterone+prednisone Placebo+prednisone 3.9 <0.001
AFFIRM 1199 Enzalutamide Placebo 4.8 <0.0001
IMPACT 512 Sipuleucel-T Placebo 4.1 =0.03
ALSYMPCA 922 Radium-223 Placebo 3.6 <0.001
FIGURE 3 | Development of castrate-resistant prostate cancer. Newly
diagnosed prostate cancer is composed of a group of heterogeneous cells.
The majority is hormone-sensitive. A minority are castration-resistant.
Following the initiation of ADT, castration-resistant cells have a survival
advantage and give rise to a more aggressive castration-resistant prostate
cancer.
It is also evident that local failures can lead to a second wave of
distant metastases (50). Achieving improved local control within
the prostate therefore carries promise of reducing the sequelae
attributable to uncontrolled local disease as well as the prevention
of new metastases.
Prostate cancer growth is dependent on androgen activation of
androgen receptors. ADT decreases testicular androgens. Although
testes are the major source of testosterone in normal men, the
intratumoral synthesis of testosterone from weak adrenal andro-
gens appears to be a substantial source of intraprostatic androgen
following ADT (51). Intraprostatic androgen synthesis may pro-
tect primary prostate cancer cells from ADT and provide a sanc-
tuary for prostate cancer cells to progress to castrate resistance.
We propose that SBRT may eliminate this sanctuary delaying the
emergence of castrate resistance.
RATIONALE FOR TREATMENT OF BONE OLIGOMETASTASES
Prostate cancer has a tropism for bone, making it the most com-
mon, and frequently the only, site of metastatic disease (52–54).
Greater than 80% of men with metastatic prostate cancer have
radiographic evidence of bone involvement. Skeletal complica-
tions are a major cause of morbidity in men with prostate cancer.
Early in the natural history of the disease, bone metastases are
generally asymptomatic, but ultimately at least 40% of patients
will be affected by bone pain, 20% will experience a pathologic
fracture, and 5% will develop a spinal cord compression. Collec-
tively, skeletal metastases can lead to decreased performance status
and devastating neurologic injury. Bone-targeted therapy, such as
zoledronic acid and denosumab, decrease but do not eliminate the
morbidity associated with bone lesions (55–57). Radiation ther-
apy is typically reserved for symptomatic disease, when the burden
of disease is greater and morbidity such as fracture may not be
avoidable. Delaying radiation therapy to this point might limit its
efficacy in reducing bone morbidity.
Recent reports have suggested that SBRT is safe and effective in
treating bone lesions involving long bones and the spinal column
(58, 59). Earlier studies administered hypofractionated regimens
more similar to conventional radiotherapy delivery with doses of
50 Gy in 10 fractions (21). Several questions remain given the
lack of long-term data compared to more conventional radiation
therapy. No optimal SBRT regimen has been established due to
the variation in target volume and proximity to normal structures
(60). However, SBRT has been administered up to 48 Gy in 3 frac-
tions to multiple metastatic sites simultaneously, and results have
shown promising long-term disease control with minimal grade
3+ toxicity (61). The potential benefits of combining radiation
with systemic agents has also been demonstrated (62, 63).
Patients treated with SBRT at oligometastatic sites have demon-
strated excellent outcomes. Among a cohort of patients with
oligometastatic disease and detectable PSA, 100% achieved local
control with SBRT to the metastatic lesions, and over half
the patients achieved an undetectable or declining PSA by a
median follow up of 4.8 months (64). In another study of men
with oligometastases following prostate treatment, salvage SBRT
deferred initiation of ADT with a 2-year local control rate of 100%
and a clinical progression-free survival of 42% (65). Neither study
observed grade 3+ toxicity. Larger studies with more homoge-
neous patient populations are required to define the potential
benefits of SBRT in the setting of prostate cancer. In addition, fur-
ther research is needed to determine the potential impact of SBRT
on systemic disease when combined with immunostimulating
agents such as sipuleucel-T (66).
Limited data exist on how radiation dose and fractionation
affect the risk of fracture following radiation therapy. Pathologic
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FIGURE 4 | Seventy-five-year-old gentleman with oligometastatic
prostate cancer and aT11 vertebral body metastasis. The decision was
to proceed with ADT and SBRT. ADT was initiated. The vertebral body was
treated with 30 Gy in 5 fractions. Treatment planning axial computed
tomography images demonstrating the GTV (red) and spinal cord (yellow).
Isodose lines shown as follows: 100% of the prescription dose (light blue
line) and 50% of the prescription dose (dark blue line). The maximum point
to the spinal cord and esophagus were 30 and 35 Gy, respectively (69).
vertebral body fractures have been described in patients treated
with SBRT. They are more common when the lesion is lytic and
≥20% of the vertebral body is involved (67). Vertebral body frac-
ture progression may occur in 40% of vertebrae treated with
single-dose SBRT (67). Treating patients early in the disease course
to decrease the extent of bone/vertebral body involvement at
the time of SBRT treatment and fractionation may reduce the
likelihood of normal bone injury (Figure 4) (68).
TREATMENT TOXICITY AND QUALITY OF LIFE
We hypothesize that SBRT will decrease tumor burden in the
prostate and bone and hence improve long-term well-being. How-
ever, if SBRT to the prostate and oligometastases caused a sig-
nificant rate of high-grade late toxicity and/or adversely affected
patients’ long-term quality of life this approach would not be
worth pursuing further. Prostate SBRT may cause urinary and
rectal injury while bone SBRT may promote fractures. The sever-
ity and duration of these toxicities varies among patients and
has never been prospectively assessed in this patient population.
Patients receiving primary ADT have a quality of life that is
indistinguishable from a matched normal male population and
a quality of life significantly better than that of men with castrate-
resistant disease (70). Our experience suggests that prostate SBRT
will not adversely affect this (71).
CONCLUSION
Castrate-resistant prostate cancer remains a complex and incur-
able disease. ADT is successful in delaying the progression to
castrate-resistant disease and improving overall survival. Unfortu-
nately, castrate-resistant clones may be present early in the disease
process even prior to initiation of ADT, creating the need for
alternative treatments. Several chemotherapeutic agents have been
developed to treat metastatic prostate cancer, but the benefits of
these drugs have been small to date. Radiation therapy is effective
for treating bone metastases but is typically reserved for late-stage,
symptomatic disease. SBRT has been demonstrated as a safe and
efficacious modality for bone lesions. Implementation of SBRT
early in the disease process may decrease the morbidity associated
with bone lesions and reduce overall tumor burden, in turn delay-
ing progression of disease and improving both the quality and
length of life.
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